Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111720 | 0.84 | HRH3 (0.50) | HRH3TDP1HTR2AHTR7HTR6 | |
| SCHEMBL6707980 | 0.82 | DRD2 (0.56) | HRH3TDP1HTR2AHTR7HTR6 | |
| SCHEMBL11066008 | 0.78 | NOS3 (0.51) | HRH3HTR2ADRD4MEN1KMT2A | |
| SCHEMBL6710735 | 0.77 | SLC6A4 (0.68) | HRH3MEN1KMT2ASLC6A4HTR1B | |
| SCHEMBL6708061 | 0.77 | SMN1; SMN2 (0.61) | HRH3DRD4MEN1KMT2ADRD2 | |
| SCHEMBL11065888 | 0.77 | DRD2 (0.48) | HRH3HTR2ADRD4SLC6A4DRD2 | |
| Hydrochloric Acid SCHEMBL11073301 | 0.76 | SMN1; SMN2 (0.63) | HRH3DRD4MEN1KMT2ADRD2 | |
| SCHEMBL11068915 | 0.76 | DRD2 (0.60) | HRH3HTR2ADRD4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11066446 | 0.76 | DRD2 (0.59) | HRH3HTR2ADRD4MEN1KMT2A | |
| SCHEMBL16902862 | 0.75 | MEN1 (0.51) | TDP1DRD4MEN1KMT2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | HRH3 1492/4885TDP1 4754/4885HTR2A 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.